Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.40 |
| ▸ | PPARD | Q03181 | 3/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4845185 | 0.95 | GAA (0.37) | PTGDR2PTGDRPPARDGAAALDH1A1 | |
| SCHEMBL4845042 | 0.94 | PPARD (0.41) | PTGDR2PPARDPPARGPPARARXRA | |
| SCHEMBL4838970 | 0.92 | PPARD (0.39) | PTGDR2PPARDPPARGPPARARXRA | |
| SCHEMBL4838429 | 0.90 | PPARD (0.36) | PPARDPPARGPPARAALDH1A1FFAR4 | |
| SCHEMBL4841159 | 0.90 | RORC (0.40) | PTGDR2PTGDRMMP8 | |
| SCHEMBL4845420 | 0.90 | FFAR4 (0.43) | RXRARXRBRXRGALDH1A1FFAR4 | |
| SCHEMBL4841606 | 0.90 | FFAR4 (0.43) | RXRARXRBRXRGALDH1A1FFAR4 | |
| SCHEMBL4844578 | 0.89 | RORC (0.35) | PPARDALDH1A1FFAR4MMP8 | |
| SCHEMBL4842320 | 0.89 | RXRA (0.41) | PTGDR2PTGDRRXRARXRBRXRG | |
| SCHEMBL4843247 | 0.86 | FFAR4 (0.40) | ALDH1A1SMN1; SMN2FFAR4MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | PTGDR2 2918/4885PTGDR 2137/4885PPARD 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.